In NSCLC harbouring exon 19 EGFR deletions, the erlotinib-cisplatin combination allowed to inhibit both HIF-1α and VEGF pathways, and was associated with greater responses [322], suggesting a potential interest in mutant-EGFR NSCLC with a resistance to EGFR-TKIs supported by hypoxia. Here, EGFR is linked to non-small cell lung carcinoma.